The evaluation of clinical results from dual targeting of the PI3K-AKT-mTOR and RAS-MEK-ERK pathways in individuals with cancer has shown the potential for efficacy but also greater toxicity (Shimizu et al., 2012). This evidence concerns the gene MTOR and cancer.